FDA tentatively OKs Teva generic for idiopathic pulmonary fibrosis

The FDA has tentatively approved Teva Pharmaceutical Industries’ (TEVA -0.5%) generic pirfenidone for the treatment of idiopathic (cause unknown) pulmonary fibrosis.

Tentative approval means that the company’s application met the standards for approval but patent issues need to be resolved before full approval is granted.

https://seekingalpha.com/news/3607930-fda-tentatively-oks-teva-generic-for-ideopathic-pulmonary-fibrosis